Solid Biosciences (NASDAQ:SLDB) Insider Jessie Hanrahan Sells 4,134 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB) insider Jessie Hanrahan sold 4,134 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $5.82, for a total value of $24,059.88. Following the sale, the insider owned 74,318 shares of the company’s stock, valued at $432,530.76. The trade was a 5.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jessie Hanrahan also recently made the following trade(s):

• On Wednesday, February 4th, Jessie Hanrahan sold 12,348 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total value of $79,521.12.
• On Monday, February 2nd, Jessie Hanrahan sold 26,535 shares of Solid Biosciences stock. The stock was sold at an average price of $6.44, for a total transaction of $170,885.40.
• On Monday, February 2nd, Jessie Hanrahan sold 26,535 shares of Solid Biosciences stock. The shares were sold at an average price of $6.44, for a total transaction of $170,885.40.
• On Wednesday, December 3rd, Jessie Hanrahan sold 4,483 shares of Solid Biosciences stock. The stock was sold at an average price of $5.11, for a total transaction of $22,908.13.

Solid Biosciences Trading Up 7.6%

Shares of NASDAQ SLDB opened at $5.92 on Thursday. The stock has a market cap of $461.23 million, a PE ratio of -2.38 and a beta of 2.67. Solid Biosciences Inc. has a 12-month low of $2.41 and a 12-month high of $7.37. The company has a 50-day moving average of $5.95 and a 200 day moving average of $5.68.

Wall Street Analyst Weigh In

Several analysts have issued reports on SLDB shares. Needham & Company LLC restated a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a report on Monday, February 9th. Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Thursday, January 22nd. JPMorgan Chase & Co. reduced their price objective on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Finally, Chardan Capital reiterated a “buy” rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Solid Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.70.

Hedge Funds Weigh In On Solid Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc lifted its holdings in shares of Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after purchasing an additional 4,063 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in Solid Biosciences by 205.5% in the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after buying an additional 4,534 shares during the last quarter. Creative Planning acquired a new stake in shares of Solid Biosciences in the second quarter valued at approximately $57,000. Russell Investments Group Ltd. grew its position in shares of Solid Biosciences by 142.0% during the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after acquiring an additional 5,991 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Solid Biosciences by 233.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock valued at $74,000 after acquiring an additional 10,585 shares during the period. 81.46% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Neutral Sentiment: Coverage explaining the intraday lift — AAII published an item titled “Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 7.64%” that summarizes market reaction and likely drivers for the rise; read it for context. Why SLDB Stock Is Up
• Neutral Sentiment: Technical and valuation context: 12‑month range roughly $2.41–$7.37, market cap ≈ $461M, negative P/E (loss-making), 50‑day SMA ~$5.95 and 200‑day SMA ~$5.68 — the stock is trading near its recent highs, so momentum/coverage can amplify moves.
• Negative Sentiment: CEO Alexander Cumbo sold 16,644 shares at an average $5.82 (≈ $96,868); his post‑sale holding is 235,405 shares (down ~6.6%). Filing: CEO Sale Filing
• Negative Sentiment: CFO Kevin Tan sold 5,404 shares at an average $5.82 (≈ $31,451); post‑sale holding 99,422 shares (down ~5.2%). Filing: CFO Sale Filing
• Negative Sentiment: COO David T. Howton sold 7,469 shares at $5.82 (≈ $43,470); post‑sale holding 105,077 shares (down ~6.6%). Filing: COO Sale Filing
• Negative Sentiment: CTO Paul Herzich sold 3,616 shares at $5.82 (≈ $21,045); post‑sale holding 72,638 shares (down ~4.7%). Filing: CTO Sale Filing
• Negative Sentiment: Director Ilan Ganot sold 2,658 shares at $5.82 (≈ $15,470); post‑sale holding 27,474 shares (down ~8.8%). Filing: Director Sale Filing
• Negative Sentiment: Insider Jessie Hanrahan sold 4,134 shares at $5.82 (≈ $24,060); post‑sale holding 74,318 shares (down ~5.3%). Filing: Insider Sale Filing

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.